Joel Silver, MD
Hematology-Oncology · Hartford, CTNPI 1013976299
Payments from drug & device makers
Across 196 payments — averaging $292.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cornerstone Specialty Network LLC$34K
- Daiichi Sankyo Inc.$14K
- Astellas Pharma US Inc$4K
- Seagen Inc.$1K
- AstraZeneca$1K
- Sanofi-aventis U.S. LLC$328
- plus $2K from 33 others
What the payments were for
- Consulting fees$19,41634%
- Speaking & faculty fees$32,14556%
- Travel & lodging$2,0714%
- Food & beverage$2,8805%
- Education$7481%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cornerstone Specialty Network LLC | 28 | $33,926 |
| Daiichi Sankyo Inc. | 14 | $14,154 |
| Astellas Pharma US Inc | 4 | $4,059 |
| Seagen Inc. | 4 | $1,417 |
| AstraZeneca(2 entities) | 13 | $1,306 |
| Sanofi-aventis U.S. LLC | 5 | $328 |
| Johnson & Johnson(2 entities) | 12 | $271 |
| E.r. Squibb & Sons, L.L.C. | 13 | $204 |
| Genentech USA, Inc. | 13 | $171 |
| Novartis | 10 | $145 |
| Pfizer | 10 | $125 |
| Epizyme, Inc. | 1 | $100 |
| Bristol Myers Squibb | 6 | $85 |
| Sanofi | 5 | $82 |
| Bayer | 5 | $71 |
| Merck | 5 | $70 |
| Lilly USA, LLC | 5 | $69 |
| Eisai Inc. | 4 | $68 |
| Tesaro, Inc. | 3 | $64 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $46 |
| Amgen | 3 | $45 |
| Exelixis Inc. | 3 | $44 |
| Karyopharm Therapeutics Inc. | 3 | $37 |
| Heron Therapeutics, Inc. | 2 | $33 |
| Tersera Therapeutics LLC | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $31 |
| Ipsen Biopharmaceuticals, Inc | 2 | $30 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $30 |
| Incyte Corporation | 2 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Gilead | 2 | $27 |
| GSK | 1 | $17 |
| Verastem, Inc. | 1 | $16 |
| Fortovia Therapeutics, Inc. | 1 | $16 |
| Taiho Oncology, Inc. | 1 | $15 |
| EMD Serono, Inc. | 1 | $15 |
| Dova Pharmaceuticals | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology-oncology providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 53 | $1,212,430 |
| RevlimidLenalidomide | 47 | $795,841 |
| BrukinsaZanubrutinib | 35 | $611,167 |
| XtandiEnzalutamide | 27 | $518,819 |
| XpovioSelinexor | 15 | $416,306 |
| ImbruvicaIbrutinib | 33 | $403,594 |
| IbrancePalbociclib | 27 | $373,955 |
| Lenalidomide | 35 | $342,499 |
| CalquenceAcalabrutinib Maleate | 19 | $282,071 |
| LenvimaLenvatinib Mesylate | 11 | $272,138 |
| LonsurfTrifluridine/Tipiracil Hcl | 12 | $233,945 |
| BesremiRopeginterferon Alfa-2b-Njft | 13 | $219,018 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $193,585 |
| TafinlarDabrafenib Mesylate | 13 | $192,058 |
| Sunitinib Malate | 12 | $108,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $204 | $1,212,43053 claims |
| Bristol Myers SquibbRevlimid | $85 | $795,84147 claims |
| Astellas Pharma US IncXtandi | $4,059 | $518,81927 claims |
| PfizerIbrance, Eliquis | $125 | $443,91590 claims |
| Karyopharm Therapeutics Inc.Xpovio | $37 | $416,30615 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $46 | $403,59433 claims |
| NovartisMekinist, Tafinlar | $145 | $385,64225 claims |
| AstraZenecaCalquence | $1,306 | $282,07119 claims |
| Eisai Inc.Lenvima | $68 | $272,13811 claims |
| Taiho Oncology, Inc.Lonsurf | $15 | $233,94512 claims |
| Johnson & JohnsonXarelto | $271 | $75,30776 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Other hematology-oncology in Hartford
- Carolyn RayHartford$0
- Charanjeev KapoorManchester$17K
- Mojisola AraoyeFarmington$188
- Kathleen FennNew Haven$0
- Michael ChiorazziNew Haven$0
- Jia LiWest Haven$0
- Jeremy JacoxNew Haven$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.